LCD Reference Article Article

Response to Comments for MolDX: Genomic Health™ Oncotype DX® Prostate Cancer Assay

A54613

Expand All | Collapse All
Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website.
Draft Article
Draft Articles are works in progress and not necessarily a reflection of the current billing and coding practices. Revisions to codes are carefully and thoroughly reviewed and are not intended to change the original intent of the LCD.

Document Note

Note History

Contractor Information

Article Information

General Information

Source Article ID
N/A
Article ID
A54613
Original ICD-9 Article ID
Not Applicable
Article Title
Response to Comments for MolDX: Genomic Health™ Oncotype DX® Prostate Cancer Assay
Article Type
Article
Original Effective Date
10/05/2015
Revision Effective Date
10/05/2015
Revision Ending Date
N/A
Retirement Date
N/A

CPT codes, descriptions, and other data only are copyright 2025 American Medical Association. All Rights Reserved. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. CPT is a registered trademark of the American Medical Association.

Current Dental Terminology © 2025 American Dental Association. All rights reserved.

Copyright © 2025, the American Hospital Association, Chicago, Illinois. Reproduced with permission. No portion of the AHA copyrighted materials contained within this publication may be copied without the express written consent of the AHA. AHA copyrighted materials including the UB‐04 codes and descriptions may not be removed, copied, or utilized within any software, product, service, solution, or derivative work without the written consent of the AHA. If an entity wishes to utilize any AHA materials, please contact the AHA at ub04@aha.org or 312‐422‐3366.

Making copies or utilizing the content of the UB‐04 Manual, including the codes and/or descriptions, for internal purposes, resale and/or to be used in any product or publication; creating any modified or derivative work of the UB‐04 Manual and/or codes and descriptions; and/or making any commercial use of UB‐04 Manual or any portion thereof, including the codes and/or descriptions, is only authorized with an express license from the American Hospital Association. The American Hospital Association (the "AHA") has not reviewed, and is not responsible for, the completeness or accuracy of any information contained in this material, nor was the AHA or any of its affiliates, involved in the preparation of this material, or the analysis of information provided in the material. The views and/or positions presented in the material do not necessarily represent the views of the AHA. CMS and its products and services are not endorsed by the AHA or any of its affiliates.

CMS National Coverage Policy

N/A

Article Guidance

Article Text
  1. Include Coverage for NCCN/AUA Intermediate Risk Patients

    Comment: A commenter submitted anecdotal information regarding his personal use of this assay. He said that “maturing date shows that Gleason 3+4=7 carcinoma do well on active surveillance and carry a similar cancer specific survival to those of Gleason 3+3=6. While AS (active surveillance) may not be appropriate for all intermediates, the assay (aka Genomic Prostate Score – GPS) provides my patients with the additional information needed to better understand if AS is an appropriate consideration. I strongly urge the reconsideration of approval for NCCN intermediate risk patients.” A number of other commenters also expressed coverage for intermediate risk patients.

    Another commenter writes “patients with Gleason sum 3+4 intermediate risk prostate cancer can have clinical outcomes indistinguishable from low risk disease (Raldow JAMA Oncol 2015) and recent studies indicates that between 8-16% of intermediate risk patients use AS as their primary management strategy (Shelton AUA 2015, Loeb AUA 2015).” This commenter notes that accurate risk stratification remains a challenge and believes this GPS provides an independent measure of aggressiveness.

    Response: Accurate prostate cancer risk stratification remains a challenge. The GPS assay validation studies showed that incorporation of GPS results with clinical assessment more accurately identified very low- and low risk biological potential, and thus, appropriate candidates for AS. Despite limited data from the validation studies that suggested some intermediate patients with a low GPS benefit from AS, the NCCN and other medical groups do not recommend this approach.

    Prospective clinical studies are ongoing by the test manufacturer aimed at addressing the clinical utility of GPS for intermediate risk patient. The results of these studies may allow Medicare coverage of intermediate risk patients in the future.

  2. Life Expectancy of 10-20 Years

    Comment: A commenter disagrees with the coverage requirement of 10-20 years. He indicates that “life expectancy should not limit the opportunity to utilize this important piece of data that will impact shared decision making at the time of diagnosis.” He also indicates “by accepting patients of all life expectancy, we can avoid any bias in our utilization and offer the same resources to all patients.

    Another commenter writes that “a life expectancy of = 10 years makes much more sense as it falls in line with NCCN guidelines and with the usual clinical approach to life expectancy assessments.” He indicated that capping life expectancy at 20 years does not make intuitive or clinical sense stating “Why would a patient whose life expectancy is = 20 years not qualify for risk stratification with this assay?”

    Response: Since coverage is predicated on prospective longitudinal data which for prostate cancer may require 10-20 years, little to no data would be forthcoming if the assay was used for patients with significantly shorter life expectancies. The purpose of this policy is to provide Medicare coverage for an assay with very limited clinical utility (assay results in improved patient outcomes) that would not otherwise be covered due to very limited prospective utility.

    The life expectancy criteria has been changed to = 10 years.

  3. CTR (Certification and Training Registry) Program

    Comment: CTR appears to be a valid concept to ensure the proper utilization and tracking of outcomes. The commenter states that “the reality though is that this type of program will impact and prove excessive burden on myself and office staff to complete this additional data capture.” The commenter suggests that the detail of the CTR be reconsidered.

    Response: The data capture consists of requisite patient information on the test requisition and biennial (2x/yr) submission of prostate cancer-related morbidity or mortality, (if any). This does not constitute an excessively burdensome requirement for coverage.

  4. Prevent Unnecessary Harms of Definitive Treatment

    Comment: One commenter said that patients are often scared when they are first diagnosed with prostate cancer and are wary of the concept of AS. He indicates that use of this assay has provided reassurance to these newly-diagnosed patients because they can easily comprehend why it is safe to intentionally delay treatment and are even provided a numerical, quantitated risk result. He also indicates that an elevated assay result can reinforce when patients who met criteria for low risk NCCN prostate cancer need to be treated.

    Response: The purpose of this Coverage with Data Development policy is to provide limited coverage for an assay with limited clinical utility (assay results in improved patient outcomes) as currently documented in existing publications. This policy support the opportunity to develop that data within the limited scope of the policy’s parameters that would not otherwise be eligible for coverage as reasonable and necessary.

  5. Patient Registry Requirements

    Comment: A commenter indicates that many of the patient registry requirements are being met in an ongoing, prospective observational trial of 1200 newly diagnosed prostate cancer patients that is being conducted by Genomic Health. The commenter hopes that the data collection will supplement the data collection under this policy to allow full coverage without data collection and CTR requirements.

    Response: Unconditional coverage predicated on solid scientific data for low and intermediate risk prostate cancer patients is desired by both Genomic Health and Palmetto GBA.

  6. Correction of CGS and MolDx contractor Error

    Commenter: The current policy incorrectly states “To ensure that physicians understand the limitation of the test based on its validation through retrospective non-US based standards of care studies.”

    Response: CGS and the MolDx contractor apologizes for the incorrect statement and recognizes that Genomic Health validations studies were all US based and used contemporary standards of care. The incorrect statement in the policy has been corrected to read: “To ensure that physicians understand the limitation of the test based on its validation.”

Response To Comments

Number Comment Response
1
N/A

Coding Information

Bill Type Codes

Code Description

Please accept the License to see the codes.

N/A

Revenue Codes

Code Description

Please accept the License to see the codes.

N/A

CPT/HCPCS Codes

Please accept the License to see the codes.

N/A

CPT/HCPCS Modifiers

Group 1

Group 1 Paragraph

N/A

Group 1 Codes

N/A

N/A

ICD-10-CM Codes that Support Medical Necessity

Group 1

Group 1 Paragraph

N/A

Group 1 Codes

N/A

N/A

ICD-10-CM Codes that DO NOT Support Medical Necessity

Group 1

Group 1 Paragraph

N/A

Group 1 Codes

N/A

N/A

ICD-10-PCS Codes

Group 1

Group 1 Paragraph

N/A

Group 1 Codes

N/A

N/A

Additional ICD-10 Information

N/A

Bill Type Codes

Contractors may specify Bill Types to help providers identify those Bill Types typically used to report this service. Absence of a Bill Type does not guarantee that the article does not apply to that Bill Type. Complete absence of all Bill Types indicates that coverage is not influenced by Bill Type and the article should be assumed to apply equally to all claims.

Code Description

Please accept the License to see the codes.

N/A

Revenue Codes

Contractors may specify Revenue Codes to help providers identify those Revenue Codes typically used to report this service. In most instances Revenue Codes are purely advisory. Unless specified in the article, services reported under other Revenue Codes are equally subject to this coverage determination. Complete absence of all Revenue Codes indicates that coverage is not influenced by Revenue Code and the article should be assumed to apply equally to all Revenue Codes.

Code Description

Please accept the License to see the codes.

N/A

Other Coding Information

Group 1

Group 1 Paragraph

N/A

Group 1 Codes

N/A

N/A

Coding Table Information

Excluded CPT/HCPCS Codes - Table Format
Code Descriptor Generic Name Descriptor Brand Name Exclusion Effective Date Exclusion End Date Reason for Exclusion
N/A N/A
N/A
Non-Excluded CPT/HCPCS Ended Codes - Table Format
Code Descriptor Generic Name Descriptor Brand Name Exclusion Effective Date Exclusion End Date Reason for Exclusion
N/A

Revision History Information

Revision History Date Revision History Number Revision History Explanation
10/05/2015 R1

Updated LCD Reference Article section.

N/A

Associated Documents

Medicare BPM Ch 15.50.2 SAD Determinations
Medicare BPM Ch 15.50.2
Related Local Coverage Documents
N/A
Related National Coverage Documents
NCDs
N/A
SAD Process URL 1
N/A
SAD Process URL 2
N/A
Statutory Requirements URLs
N/A
Rules and Regulations URLs
N/A
CMS Manual Explanations URLs
N/A
Other URLs
N/A
Public Versions
Updated On Effective Dates Status
11/07/2023 10/05/2015 - N/A Currently in Effect You are here
08/14/2015 10/05/2015 - N/A Superseded View

Keywords

N/A